HER2-Positive Early Stage Breast Cancer Completed Phase 2 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0063722 (HER2-Positive Early Stage Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01827163Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast CancerTreatment